Daan van Well - 18 Mar 2026 Form 3 Insider Report for SOPHiA GENETICS SA (SOPH)

Role
Chief Legal Officer
Signature
/s/ Elimara Brunetto as Attorney-in-Fact for Daan van Well
Issuer symbol
SOPH
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 09:46:44 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Van Well Daan Chief Legal Officer C/O SOPHIA GENETICS SA, LA PIECE 12, ROLLE, SWITZERLAND /s/ Elimara Brunetto as Attorney-in-Fact for Daan van Well 18 Mar 2026 0002006414

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SOPH Ordinary Shares 261,922 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 2,500 $3.93 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 3,000 $4.01 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 15,000 $4.21 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 39,000 $6.31 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 84,906 $18.00 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 148,699 $4.72 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 217,226 $4.96 Direct F4
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 161,932 $3.29 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 97,620 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 3,042 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 30,267 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 27,660 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 36,651 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
F2 The share options are fully vested and exercisable.
F3 The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
F4 The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
F5 The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney